CMS1, also referred to as MSI-immune, accounts for approximately 14% of CRC and is associated with MSI and CIMP phenotypes, BRAF mutations and the serrated pathway of carcinogenesis [23]. This evidence concerns the gene BRAF and colorectal carcinoma.